Skip to main content
OpenTrials
Completed

NCT Number: NCT00918736

Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis

The aim of this study was to investigate the efficacy and safety of three weekly intraarticular injections of Hyaluronate (HA) in patients with unilateral ankle Osteoarthritis (OA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Physical Medicine and Rehabilitation, Veterans General Hospital, Kaohsiung, Taiwan

Kaohsiung City, 813, Taiwan

About this study

Viscosupplementation with 3 to 5 weekly hyaluronate injections is a well-established treatment option in knee osteoarthritis. Previous studies reported that five weekly hyaluronate injections were safe and effective for the treatment of ankle osteoarthritis. However, the effect of three weekly injections has rarely been investigated. Besides, no study to date has assessed whether balance function would change after HA injections in patients with ankle OA. The purpose of this study was to evaluate the efficacy and safety of three weekly injections of sodium hyaluronate (Hyalgan) in patients with unilateral ankle osteoarthritis. Pain, physical function and balance will be assessed as parameters for the effectiveness.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • were 18 years of age or older, reported unilateral ankle pain for at least 6 months and had either reported no significant benefit from conservative treatment (rest, physical therapy, orthoses or pain medications etc.) or were unable to tolerate side effects of medications
  • ankle radiographs taken within 6 months were equivalent to grade 2 or 3 according to the Kellgren-Lawrence grading system (grade 2, definite osteophytes and possible narrowing of joint space; grade 3, moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone contour)22
  • had a current total AOS score (described below) of > 3 and < 9 (possible range, 0-10)
  • were normally active, not bedridden or confined to a wheelchair, and were able to walk 30 meters without the aid of a walker, crutches or cane
  • were willing to discontinue all nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication (except for rescue medication) for the duration of the study
  • did not receive physical therapy or trial of shoe modifications or orthotics during the study period

Exclusion criteria

  • pregnant and lactating women
  • bilateral ankle OA requiring treatment of both ankles
  • chronic ankle instability
  • lower leg trauma other than within the ankle
  • previous orthopedic surgery on the spine, hip or knee
  • presence of active joint infections of foot or ankle
  • previous surgery or arthroscopy on the ankle within 12 months
  • intraarticular steroid or HA injection in the treated ankle within the past 6 months
  • treatment with anticoagulants or immunosuppressives
  • history of rheumatoid arthritis, gout, or any other inflammatory arthropathy
  • history of avian protein allergy
  • presence of other comorbidity (neoplasm, diabetes mellitus, paresis, recent trauma, etc) or poor health status that would interfere with the clinical assessments during the study

Treatment and study plan

Sodium Hyaluronate

Drug

3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.

Primary outcomes

  1. Change From Baseline in the Ankle Osteoarthritis Scale (AOS) Score at 6 Months

    Time frame: baseline and 6 months

    The AOS is a patient-rated, validated outcome measure that includes nine items on a pain subscale and nine items on a disability subscale. Using the AOS, a score of 0 represent no pain or disability and 10 represent worst pain or disability imaginable

Secondary outcomes

  1. The American Orthopedic Foot and Ankle Society (AOFAS) Ankle/Hindfoot Score

    Time frame: 6 months

    The American Orthopedic Foot and Ankle Society (AOFAS) ankle/hindfoot score is a 100-point scale that devotes 40 points to pain, 50 points to function and 10 points to alignment. The maximum score of 100 points denotes no pain and normal function and alignment

  2. Ankle Sagittal Range of Motion

    Time frame: 6 months

    Ankle sagittal ROM is the sum of ankle dorsiflexion and plantar flexion angles.

  3. Four Clinical Balance Tests

    Time frame: 6 months

    Single-leg stance test (SLS),The Functional Reach Test (FRT),Timed " Up-and-Go" test (TUG) ,Berg Balance Scale (BBS)

  4. the Level of Global Satisfaction Based on a 7-point Categorical Scale

    Time frame: 6 months

    The rating was based on a 7-point categorical scale weighted from completely satisfied, satisfied, somewhat satisfied, no change, somewhat unsatisfied, unsatisfied to completely unsatisfied.

  5. Systemic and Local Adverse Events Recording

    Time frame: 6 months

    he occurrence of systemic and local adverse events, defined as any unwanted events whether it was thought to be related to the study drugs or not, were recorded on a diary card

  6. Rescue Acetaminophen Consumption

    Time frame: 6 months

    The use of all analgesic medication during the study period was recorded on a diary card by the patient.

Sponsors and collaborators

Lead sponsor

Kaohsiung Veterans General Hospital.

Other

Collaborators

  • National Science and Technology Council, Taiwan

Registry information

Official study title

Hyaluronans in the Treatment of Ankle Osteoarthritis

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jun 11, 2009
Registry last updated
Jun 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.